1Khuri FR,Nemunaitis J,Ganly I,et al.A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[].Nature Medicine.2000
2Khuri FR,Nemunaitis J,Ganly I,et al.A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[].Nature Medicine.2000
3Heise C,Kim DH.Replication-selective adenoviruses as onco lytic agents[].The Journal of Clinical Investigation.2000
4Heise CC,Williams AM,Xue S,Propst M,Kirn DH.Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy[].Cancer Research.1999
5Goodrum FD,Ornelles DA.The early region1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle[].Journal of Virology.1997
6Wildner O,Morris JC.The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus tk: assessment of antitumor efficacy and toxicity[].Cancer Research.2000
7Hawkins LK,Johnson L,Bauzon M,et al.Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6. 7K/gp 19K region[].Gene Therapy.2001
8Gomez-Navarro J,Curiel DT.Conditionally replicative adeno viral vectors for cancer gene therapy[].The Lancet Oncology.2000
9Shinoura N,Yoshida Y,Tsunoda R,et al.Highly augmented cytopathic effect of a fiber-mutant E1 B-defective adenovirus for gene therapy of gliomas[].Cancer Research.1999
10Suzuki K,Fueyo J,Krasnykh V,Reynolds PN,Curiel DT,Alemany R.A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency[].Clinical Cancer Research.2001
